Responses
Scientific Abstracts
Late Breaking Abstracts
Late Breaking Abstract Session
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.